News from del mar pharmaceuticals

Jan 07, 2013, 08:30 ET

Del Mar Pharmaceuticals Receives European Orphan Drug Designation for VAL-083 for the Treatment of Glioma

 Del Mar Pharma today announced that the European Committee for Orphan Medicinal Products (COMP) has recommended the designation of VAL-083 as...

Nov 15, 2012, 10:16 ET

DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting

 Del Mar Pharmaceuticals (BC) Ltd. ("DelMar Pharma") today announced that the Company will present two scientific posters at the Society for...

Nov 08, 2012, 08:30 ET

Del Mar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference

Del Mar Pharmaceuticals (BC) Ltd. (DelMar) today announced that Mr. Jeffrey Bacha, the Company's President & CEO, delivered the keynote address...

Oct 29, 2012, 08:30 ET

Del Mar Pharmaceuticals Expands Collaboration with Guangxi Wuzhou Pharmaceutical Company

Del Mar Pharmaceuticals (BC) Ltd. ("DelMar") today announced a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company, a subsidiary of...

Sep 07, 2012, 08:01 ET

Del Mar Pharmaceuticals to Present at 14th Annual Rodman & Renshaw Healthcare Conference in New York

Del Mar Pharmaceuticals today announced that Jeffrey A. Bacha, President & Chief Executive Officer, will present at the 14th Annual Rodman...

Feb 07, 2012, 10:30 ET

Del Mar Pharmaceuticals to Present New Pre-clinical Data Related to the Mechanism of VAL-083 at the AACR Annual Meeting in April 2012

 Del Mar Pharmaceuticals today announced that a pre-clinical abstract entitled, "VAL083, a novel N7 alkylating agent, surpasses...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer